vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and FIRST COMMUNITY CORP (FCCO). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $23.2M, roughly 1.4× FIRST COMMUNITY CORP). Over the past eight quarters, FIRST COMMUNITY CORP's revenue compounded faster (19.1% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

United Community is an American bank. United is one of the largest full-service financial institutions in the Southeast, with $27.7 billion in assets and 200 offices in Alabama, Florida, Georgia, North Carolina, South Carolina and Tennessee. In addition to its presence in the Southeast, United Community is the largest bank headquartered in South Carolina by total asset size.

DNA vs FCCO — Head-to-Head

Bigger by revenue
DNA
DNA
1.4× larger
DNA
$33.4M
$23.2M
FCCO
Faster 2-yr revenue CAGR
FCCO
FCCO
Annualised
FCCO
19.1%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
DNA
DNA
FCCO
FCCO
Revenue
$33.4M
$23.2M
Net Profit
$5.5M
Gross Margin
Operating Margin
-211.9%
Net Margin
23.7%
Revenue YoY
-23.8%
Net Profit YoY
37.6%
EPS (diluted)
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
FCCO
FCCO
Q1 26
$23.2M
Q4 25
$33.4M
$20.6M
Q3 25
$38.8M
$20.5M
Q2 25
$49.6M
$19.5M
Q1 25
$48.3M
$18.4M
Q4 24
$43.8M
$17.5M
Q3 24
$89.0M
$17.0M
Q2 24
$56.2M
$16.3M
Net Profit
DNA
DNA
FCCO
FCCO
Q1 26
$5.5M
Q4 25
Q3 25
$-80.8M
$5.2M
Q2 25
$-60.3M
$5.2M
Q1 25
$-91.0M
$4.0M
Q4 24
Q3 24
$-56.4M
$3.9M
Q2 24
$-217.2M
$3.3M
Operating Margin
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
-211.9%
Q3 25
-231.8%
32.2%
Q2 25
-132.1%
34.2%
Q1 25
-184.1%
28.2%
Q4 24
-236.3%
30.9%
Q3 24
-62.0%
29.5%
Q2 24
-396.7%
24.7%
Net Margin
DNA
DNA
FCCO
FCCO
Q1 26
23.7%
Q4 25
Q3 25
-207.9%
25.4%
Q2 25
-121.6%
26.6%
Q1 25
-188.2%
21.8%
Q4 24
Q3 24
-63.3%
22.7%
Q2 24
-386.4%
20.0%
EPS (diluted)
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
$-1.41
$0.62
Q3 25
$-1.45
$0.67
Q2 25
$-1.10
$0.67
Q1 25
$-1.68
$0.51
Q4 24
$-1.91
$0.55
Q3 24
$-1.08
$0.50
Q2 24
$-4.23
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
FCCO
FCCO
Cash + ST InvestmentsLiquidity on hand
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$220.8M
Total Assets
$1.1B
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
$422.6M
Q3 25
$495.5M
Q2 25
$559.4M
Q1 25
$325.3M
Q4 24
$561.6M
Q3 24
$616.2M
Q2 24
$730.4M
Stockholders' Equity
DNA
DNA
FCCO
FCCO
Q1 26
$220.8M
Q4 25
$508.6M
$167.6M
Q3 25
$559.8M
$161.6M
Q2 25
$613.0M
$155.5M
Q1 25
$647.4M
$150.0M
Q4 24
$716.1M
$144.5M
Q3 24
$797.9M
$143.3M
Q2 24
$833.1M
$136.2M
Total Assets
DNA
DNA
FCCO
FCCO
Q1 26
$2.4B
Q4 25
$1.1B
$2.1B
Q3 25
$1.2B
$2.1B
Q2 25
$1.2B
$2.0B
Q1 25
$1.3B
$2.0B
Q4 24
$1.4B
$2.0B
Q3 24
$1.5B
$1.9B
Q2 24
$1.6B
$1.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
FCCO
FCCO
Operating Cash FlowLast quarter
$-47.7M
Free Cash FlowOCF − Capex
$-47.7M
FCF MarginFCF / Revenue
-142.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
$-47.7M
$18.7M
Q3 25
$-31.6M
$9.2M
Q2 25
$-40.3M
$-236.0K
Q1 25
$-51.5M
$6.4M
Q4 24
$-42.4M
$11.6M
Q3 24
$-103.5M
$10.8M
Q2 24
$-84.4M
$-292.0K
Free Cash Flow
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
$-47.7M
$17.6M
Q3 25
$9.0M
Q2 25
$-40.3M
$-454.0K
Q1 25
$-59.1M
$6.2M
Q4 24
$-56.1M
$10.5M
Q3 24
$-118.6M
$10.6M
Q2 24
$-111.4M
$-634.0K
FCF Margin
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
-142.8%
85.3%
Q3 25
44.2%
Q2 25
-81.2%
-2.3%
Q1 25
-122.4%
34.0%
Q4 24
-128.0%
60.3%
Q3 24
-133.2%
62.5%
Q2 24
-198.2%
-3.9%
Capex Intensity
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
0.0%
5.4%
Q3 25
0.0%
0.6%
Q2 25
0.1%
1.1%
Q1 25
15.8%
1.1%
Q4 24
31.3%
6.3%
Q3 24
16.9%
1.1%
Q2 24
48.1%
2.1%
Cash Conversion
DNA
DNA
FCCO
FCCO
Q1 26
Q4 25
Q3 25
1.77×
Q2 25
-0.05×
Q1 25
1.61×
Q4 24
Q3 24
2.80×
Q2 24
-0.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

FCCO
FCCO

Net Interest Income$18.4M79%
Noninterest Income$4.8M21%

Related Comparisons